Performance evaluation of ML models for preoperative prediction of HER2-low BC based on CE-CBBCT radiomic features: A prospective study

Xianfei Chen,Minghao Li,Xueli Liang,Danke Su
DOI: https://doi.org/10.1097/md.0000000000038513
IF: 1.6
2024-06-15
Medicine
Abstract:Breast cancer (BC) is a heterogeneous disease that varies among molecular subtypes. These subtypes differ in terms of frequency, prognosis, response to treatment, and survival outcomes. [ 1 ] Approximately 45 to 55% of primary BCs exhibit low expression of the human epidermal growth factor receptor 2 (HER2), known as HER2-low. [ 2–4 ] This categorization includes a wide range of cases, including triple-negative and luminal-type hormone receptor (HR)-positive breast tumors. These patients are classified as HER2-negative BC on the current HER2 validation guidelines, which means that HER2-targeted therapies are not recommended or effective in these patients. [ 5 ] Trastuzumab deruxtecan, a novel antibody–drug conjugate, has shown promise in treating patients with HER2-low metastatic BC according to the results of the DESTINY-Breast04 study. [ 6 ] According to recent clinical research, patients with HER2-low BC have unique clinicopathological traits, with varying prognoses and rates of pathological complete response compared to HER2-zero (immunohistochemistry [IHC] score 0) BC. [ 7–9 ] Therefore, accurately distinguishing patients with HER2-low BC from HER2-negative BC is crucial for selecting the most appropriate therapy and predicting the treatment outcomes in this population.
medicine, general & internal
What problem does this paper attempt to address?